People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arrakis Therapeutics, Inc. | — | Biotechnology | Series A | $28.2M | $542.3M | 2017 |
David E. Neafus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David E. Neafus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Gaster | 1 | 7 |
| Michael Gilman | 1 | 6 |
| Raj Parekh | 1 | 5 |
| Nikola Trbovic | 1 | 3 |
| Alan E. Walts | 1 | 3 |
| Jakob Loven | 1 | 2 |
| Colleen Cuffaro | 1 | 1 |
| Colleen E. Cuffaro | 1 | 1 |
| Carolyn E. Green | 1 | 1 |
| Russell C. Petter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.